LiSyM: The better way to manage your data
Free and open platform for easier research data management
Latest additions
- Hepatocytes reprogram liver macrophages involving control of TGF-beta activation, influencing liver regeneration and injury.
Publication - added 8 days ago - ERRγ-inducible FGF23 promotes alcoholic liver injury through enhancing CYP2E1 mediated hepatic oxidative stress
Publication - added 9 days ago - Extracellular Matrix Protein 1 Attenuates Hepatic Fibrosis by Inhibiting TSP-, ADAMTS-, and MMP-Mediated Latent TGF-β1 Activation
Publication - added 9 days ago - The Interplay of TGF-β1 and Cholesterol Orchestrating Hepatocyte Cell Fate, EMT, and Signals for HSC Activation
Publication - added 9 days ago - Reciprocal Inhibitory Regulation of TGF-β1 Signaling and Cholesterol Metabolism in Hepatocytes
Publication - added 9 days ago - ECM1-Mediated Inhibition of Protease-Induced LTGF-β1 Activation in Chronic Liver Disease: Implications for Therapeutic Strategies
Publication - added 9 days ago - EGF/STAT1 signals to maintain ECM1 expression in hepatic homeostasis are disrupted by IFNγ/NRF2 in chronic liver disease
Publication - added 9 days ago - TGFβR1 inhibition drives hepatocellular carcinoma proliferation through induction of toll‐like‐receptor signalling
Publication - added 9 days ago - Lysis buffer selection guidance for mass spectrometry-based global proteomics including studies on the intersection of signal transduction and metabolism (preprint)
Publication - added 14 days ago - Tumour cells can escape antiproliferative pressure by interferon-β through immunoediting of interferon receptor expression
Publication - added 14 days ago
Find content
LiSyM (Liver Systems Medicine) represents a research network of German centers and institutions, brought together by a 20 Million Euro funding program of the German Government, in which mathematicians, modelers, pharmacologists, molecular biologists and clinical scientists work together to develop a Systems Medicine approach to study early and advanced liver disease.
The aim of this unique research program is to acquire and use new experimental data and data from existing data bases to build computational models that facilitate decision making at the patient's bedsite and to predict the actions of new medicines in the treatment of metabolic liver disease.